peginterferon alfa-2b
Overview
Categories
- 8 Antineoplastics, immunomodulators and drugs used in palliative care
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
Pipethanate ethobromide's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 1 to 1 mcg/kg/week | 1 (1) | As recommended. | Sc | Dose reduction or discontinuation is required in case of depression, haemtological and renal side effects. For patients with a history of stable cardiac disease receiving Pegnterferon alfa 2b in combination with ribavirin, dose should be reduced by half and the ribavirin dose by 200mg/day if a 2g/dL decrease in hemoglobin is observed during any 4 week period. Both Peginterferon alpha 2b and ribavirin should be permanently discontinued if patients have hemoglobin levels <12 g/dL after this ribavirin dose reduction. |
| 1.5 to 1.5 mcg/kg/week | 1.5 (1.5) | As recommended. | Sc | when it is used in combination with ribavirin. |
Paedriatic Dosage (20kg)
|
| 60 to 0 mcg/m2/week | 30 (30) | As recommended. | Sc | This is the dose when given in combination with ribavirin |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of Pipethanate ethobromide is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
Pipethanate ethobromide
Back to top
Manufacturers of
peginterferon alfa-2b
in Pakistan
Back to top
Previous Drug Generic - Next Drug Generic